Officially registered in Laos, NeoFipronis® (Pronidesivir) provides a traceable, quality-controlled oral GS-441524 veterinary product option for cats with feline infectious peritonitis.
Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has officially launched as an oral GS-441524 veterinary tablet for cats with feline infectious peritonitis, commonly known as FIP.
NeoFipronis® is the brand name of Pronidesivir, while GS-441524 is the active pharmaceutical ingredient. The product has been officially registered in Laos and is now available through authorized channels, marking an important step toward a more standardized, traceable, and quality-controlled approach to FIP-related treatment management.
Feline infectious peritonitis is a serious and life-threatening disease in cats. For many years, FIP was considered one of the most difficult feline diseases to manage. With the development and clinical application of GS-441524, FIP treatment has entered a new stage, giving veterinarians and cat owners more options for managing this challenging disease.
NeoFipronis® (Pronidesivir) Oral Tablets are designed for convenient oral administration during FIP treatment. Compared with injectable options, oral tablets may help reduce stress for cats and improve daily administration compliance during longer treatment courses.
Each batch of NeoFipronis® (Pronidesivir) is manufactured under controlled quality standards and supported by batch traceability and product verification. This helps veterinarians, distributors, and cat owners identify authentic products and reduce the risks associated with unverified or unauthorized sources.
The launch of NeoFipronis® (Pronidesivir) reflects a continued commitment to providing a reliable, traceable, and veterinarian-guided oral GS-441524 product option for cats affected by FIP.
FIP diagnosis, dosage planning, treatment duration, and monitoring should be guided by a licensed veterinarian or qualified animal health professional. Treatment decisions should be based on the cat’s clinical condition, body weight, laboratory results, disease type, and professional veterinary judgment.
Cat owners and partners are encouraged to purchase products only through authorized channels. Unverified products may carry risks such as inconsistent composition, inaccurate dosage, lack of traceability, or uncertain quality.
With the official launch of NeoFipronis® (Pronidesivir), the brand aims to support a more transparent, standardized, and quality-focused approach to FIP-related treatment access.